AQST — Aquestive Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $490.62m
- $495.93m
- $44.55m
- 13
- 10
- 80
- 25
Annual cashflow statement for Aquestive Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -70.5 | -54.4 | -7.87 | -44.1 | -83.8 |
| Depreciation | |||||
| Non-Cash Items | 36.3 | 10.2 | 5.49 | 17.6 | 18.6 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.73 | 32 | -5.34 | -9.96 | 12.2 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -33 | -9.79 | -6.38 | -35.8 | -52.4 |
| Capital Expenditures | -0.913 | -2.52 | -0.995 | -0.159 | -0.562 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Cash from Investing Activities | -0.913 | -2.52 | -0.995 | -0.159 | -0.562 |
| Financing Cash Flow Items | -0.014 | -0.003 | 9.2 | -1.11 | -0.821 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 30.1 | 11.6 | 3.97 | 83.6 | 103 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -3.78 | -0.751 | -3.4 | 47.7 | 49.6 |